Bio-TechneTECH

Keep

Keep what you own, but don't buy more for now.

5 good· Profit growth
3 to watch· Funds trimming

$72.86+0.06 (+0.08%)

Price at 3:01 PM ET

After hours · opens in 17h 23m

NASDAQ · Healthcare · Life Sciences Tools & Services · Large company

Tell me when TECH moves 5% in a day

Read the full report on TECH with a free account

The full report adds the whole brief, the scorecard and how the call has moved.A free account gets it on three stocks you pick, plus three long research reports a month.

What would change it

Sources

Yahoo Finance daily closes to Nov 11

Any one could move it to Sell some

Compared with the S&P 500

4 points
worse in one day
8 points
worse in five trading days

+23.8% in a yearsince Nov 11, 2025

Earnings report

The news behind our call

written yesterday, 6:28 PM ETYesterday, 6:28 PM ET · 6 articles · 4 sources

Bio-Techne reported fiscal first-quarter revenue of $299.7 million.
Merck KGaA’s agreed $73-per-share cash acquisition gives Bio-Techne shareholders a defined value anchor.
Protein Sciences powered the latest quarter, showing Bio-Techne has a specific business engine supporting revenue.
Health Care has broad stock participation and improving trading conditions.

What changed

From Yahoo Finance, Benzinga, Bio-Techne via Yahoo Finance and 1 more

Bio-Techne ended the reported earnings day essentially unchanged, while valuation and growth metrics remained demanding.

Nov 13

tomorrow

Next ex-dividend date

$0.32 a share a year at the current rate.

Merck KGaA raises 2026 outlook as Bio-Techne deal nears completion
Today
Bio-Techne ended the reported earnings day essentially unchanged, while valuation and growth metrics remained demanding.
Reported EPS is unknown; the pre-print consensus estimate was $0.40, but no actual result or beat/miss can be confirmed. No explicit post-earnings guidance or management commentary was provided; forward EPS growth estimates ranged from 6.9% to 15.0%.
Earnings · Yesterday
Stock market: Will S&P 500 open up or down today?
Tuesday
TECH Q1 earnings & revenues beat, Merck KGaA merger deal advances
Monday
Bio-Techne (TECH), what is behind the Fresh attention now?
Nov 4
BIO-TECHNE DECLARES DIVIDEND
Nov 3
Bio-Techne's Q1 earnings on Deck: What's in Store for the stock?
Nov 2
Analyst ratings shifted: 1 fewer buy, 1 more sell
0 buy, 12 hold, 1 sell, against 1 buy, 12 hold, 0 sell the month before.
Analysts · Last month

Overview

In plain numbers

Revenue grew 0.9% from a year earlier, to $1.2B in the last twelve months.
It keeps 21 cents of every revenue dollar as operating profit, down from 25 cents in FY 2022.
It turned 25% of revenue into free cash flow: $308.2M in the last twelve months.
It holds $350.0M in cash and investments against $285.6M of debt, which leaves $64.5M of net cash.

Key figures

Revenue (TTM): $1.2B
Revenue growth, 1 year: +0.9%
Net income: $172M
EPS (diluted): $1.10
Gross margin: 66.2%
Operating margin: 21.4%

Return on equity: 8.3%
Return on capital: 9.4%
Debt / equity: 0.13
Current ratio: 2.28
Dividend yield: 0.44%
Buyback yield: 0.71%

Key facts

Company value: $11.4B
Price / last year's earnings: 102.9×
Today's range: 72.8072.86
Past year's range: 43.1772.86

Yesterday's close: $72.80
Swings vs the market: 1.3×about the same
Dividend yield: 0.44%$0.32 a year

What would change it

Any one could move it to Sell some

Compare TECH with